Silence Therapeutics Files Q2 2024 Financials

TL;DR

Silence Therapeutics dropped Q2 financials on Aug 15th - check the numbers.

AI Summary

Silence Therapeutics plc filed a 6-K on August 15, 2024, presenting its unaudited financial statements for the periods ending June 30, 2024. The filing includes condensed consolidated interim financial statements, Management's Discussion and Analysis, and Risk Factors for the three and six months ended June 30, 2024.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Silence Therapeutics, crucial for assessing the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not introduce new material risks.

Key Players & Entities

• Silence Therapeutics plc (company) — Registrant
• August 15, 2024 (date) — Filing Date
• June 30, 2024 (date) — Reporting Period End Date

FAQ

Filing Documents

• sln-6-k-q2_24.htm (6-K) — 28KB
• sln-ex99_1.htm (EX-99.1) — 1037KB
• 0000950170-24-097383.txt ( ) — 1065KB

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F  Form 40-F  Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  On August 15, 2024, Silence Therapeutics plc published its unaudited financial statements for the three and six months ended June 30, 2024. The unaudited condensed consolidated interim financial statements, as well as the Management’s Discussion and Analysis and Risk Factors sections, are attached hereto as Exhibit 99.1 to this Report on Form 6-K. This Report on Form 6-K (including Exhibit 99.1) shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Nos. 333-248682 and 333-273576) and Form F-3 (File Nos. 333-248203, 333-260265 and 333-279185) of Silence Therapeutics plc and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit No. Description 99.1 Report for the Three and Six Months Ended June 30, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Silence Therapeutics plc By: /s/ Craig Tooman Name: Craig Tooman Title: President and Chief Executive Officer Date: August 15, 2024

View Full Filing

View this 6-K filing on SEC EDGAR